INOVIO Announces Pricing of Approximately $75 Million Public Offering

1 source1 article First seen 21 hours ago Updated 21 hours ago United States Truth score 34

Save Like Comments Compare coverage

Summary

PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing…

Description from Amherst Bee.

Who is covering this

Amherst Bee Not rated US 21 hours ago
INOVIO Announces Pricing of Approximately $75 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today...

Comments

Comments need JavaScript.

Truth score

34/100Weakly supported

Independent outlets: 1
Source reliability: Not rated
Sides of the spectrum covering it: 0/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

No rated outlets yet

Left: 0
Centre: 0
Right: 0
Not rated: 1

How lean is counted

Source quality

Average reliability: Not rated
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

INOVIO Announces Pricing of Approximately $75 Million Public Offering

Summary

Who is covering this

Comments